Fig. 1. Low METTL3 expression in PTC and ATC leads to an immunosuppressive TME and resistance to ICB therapy.

A, B GO analysis of the bulk RNA-seq data showing enriched pathways and (C, D) ImmuCellAI analysis showing immune cell infiltration in the METTL3^low and METTL3^high PTC and ATC tissues (PTC: METTL3^low group n = 250, METTL3^high group n = 253; ATC: METTL3^low group n = 10, and METTL3^high group n = 10). E, F Identification of infiltrating cell types in PTC (n = 7) and ATC (n = 5) tissues using scRNA-seq data. G GO analysis of enriched pathways and (H) bubble plots showing TNF, IFN, IL-1 and IL-12-related ligand-receptor interactions in T cells and Tregs in the METTL3⁺ and METTL3⁻ PTC and ATC tissues.